ARTICLE | Clinical News
LMS-611 regulatory update
June 27, 2011 7:00 AM UTC
The European Commission granted Orphan Drug designation for Lamellar's LMS-611 to treat cystic fibrosis (CF). The company plans to start Phase I testing of the surface active phospholipid for the indi...